|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 601 13th Street NW |
Address2 | Suite 290 North |
| City | Washington |
State | DC |
Zip Code | 20005 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 400693064-51
|
||||||||
|
6. House ID# 415240004
|
||||||||
| TYPE OF REPORT | 8. Year | 2024 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Melanie Nathanson |
Date | 12/29/2024 10:37:11 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 10545 - The Continuing Appropriations and Extensions Act, 2025 - Issues related to funding government departments and agencies responsible for administering programs that support prescription drug coverage.
CMS Rules and Regulations focused on the promulgation of the Medicare Part D program.
S. 1542 - The DRUG Act - Issues related to ensuring that policies contemplated by Congress allow entities providing coverage of prescription medications have the tools they need to keep drugs affordable and accessible in the commercial market.
H.R. 7623 - Telehealth Modernization Act of 2024 - Support for the underlying telemedicine extension, yet concern for the commercial delinking offset included in the legislation.
S. 2973 - Modernizing and Ensuring PBM Accountability Act - Issues related to the important role PBMs play in keeping drug prices low for public and private employers and their employees.
S. 3430 Better Mental Health Care, Lower Cost Prescription Drugs and Extenders Act of 2023- Issues related to pharmacy benefit managers and their role in keeping drug prices lower for patients.
H.R. 3561 - The PATIENT Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors.
H.R. 5378 - Lower Costs, More Transparency Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors.
S. 1967 - The PBM Act - Issues related to delinking and limiting current tools used by PBMS to manage pharmacy benefits in Medicare.
S. 1339 - The Pharmacy Benefit Manager Reform Act - Issues focused on limiting spread pricing and requiring rebate pass through and other tools used to control the price of prescription medications.
S. 127 - The PBM Transparency Act - Issues related to the study of Pharmacy Benefit Managers by the Federal Trade Commission.
S. 150 - Affordable Prescriptions for Patients Act - Issues related to ensuring that people's access to affordable medications are not impeded and innovations to ensure fair pricing structures are promulgated to their fullest.
Issues related to prescription drug supply chain integrity and transparency.
Issues related to the implementation of the Inflation Reduction Act for purposes of ensuring access to affordable medications for Medicare beneficiaries and people across the United States.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Melanie |
Nathanson |
|
|
|
Megan |
Hauck |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 10545 - The Continuing Appropriations and Extensions Act, 2025 - Issues related to funding government departments and agencies responsible for administering programs that support prescription drug coverage.
CMS Rules and Regulations focused on the promulgation of the Medicare Part D program.
S. 1542 - The DRUG Act - Issues related to ensuring that policies contemplated by Congress allow entities providing coverage of prescription medications have the tools they need to keep drugs affordable and accessible in the commercial market.
H.R. 7623 - Telehealth Modernization Act of 2024 - Support for the underlying telemedicine extension, yet concern for the commercial delinking offset included in the legislation.
S. 2973 - Modernizing and Ensuring PBM Accountability Act - Issues related to the important role PBMs play in keeping drug prices low for public and private employers and their employees.
S. 3430 Better Mental Health Care, Lower Cost Prescription Drugs and Extenders Act of 2023- Issues related to pharmacy benefit managers and their role in keeping drug prices lower for patients.
H.R. 3561 - The PATIENT Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors.
H.R. 5378 - Lower Costs, More Transparency Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors.
S. 1967 - The PBM Act - Issues related to delinking and limiting current tools used by PBMS to manage pharmacy benefits in Medicare
Issues related to prescription drug supply chain integrity and transparency.
Issues related to the implementation of the Inflation Reduction Act for purposes of ensuring access to affordable medications for Medicare beneficiaries and people across the United States.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Melanie |
Nathanson |
|
|
|
Megan |
Hauck |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
H.R. 10545 - The Continuing Appropriations and Extensions Act, 2025 - Issues related to funding government departments and agencies responsible for administering programs that support prescription drug coverage.
CMS Rules and Regulations focused on the promulgation of the Medicare Part D program.
S. 1542 - The DRUG Act - Issues related to ensuring that policies contemplated by Congress allow entities providing coverage of prescription medications have the tools they need to keep drugs affordable and accessible in the commercial market.
H.R. 7623 - Telehealth Modernization Act of 2024 - Support for the underlying telemedicine extension, yet concern for the commercial delinking offset included in the legislation.
S. 2973 - Modernizing and Ensuring PBM Accountability Act - Issues related to the important role PBMs play in keeping drug prices low for public and private employers and their employees.
S. 3430 Better Mental Health Care, Lower Cost Prescription Drugs and Extenders Act of 2023- Issues related to pharmacy benefit managers and their role in keeping drug prices lower for patients.
H.R. 3561 - The PATIENT Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors.
H.R. 5378 - Lower Costs, More Transparency Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors.
S. 1967 - The PBM Act - Issues related to delinking and limiting current tools used by PBMS to manage pharmacy benefits in Medicare.
S. 1339 - The Pharmacy Benefit Manager Reform Act - Issues focused on limiting spread pricing and requiring rebate pass through and other tools used to control the price of prescription medications.
S. 127 - The PBM Transparency Act - Issues related to the study of Pharmacy Benefit Managers by the Federal Trade Commission.
S. 150 - Affordable Prescriptions for Patients Act - Issues related to ensuring that people's access to affordable medications are not impeded and innovations to ensure fair pricing structures are promulgated to their fullest.
Issues related to prescription drug supply chain integrity and transparency.
Issues related to the implementation of the Inflation Reduction Act for purposes of ensuring access to affordable medications for Medicare beneficiaries and people across the United States.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Melanie |
Nathanson |
|
|
|
Megan |
Hauck |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |